Baseline demographic characteristics in the two study groups
| MRa group (n=18) | Control group (n=12) | p Value | |
| Age (years) | 43.33±8.22 | 44.08±9.08 | 1.000* |
| Gender (male:female) | 15:3 | 10:2 | 1.000† |
| Duration of symptoms (weeks) | 3.42±2.69 | 3.21±1.53 | 0.662* |
| BCVA (logMAR) | 0.28±0.22 | 0.28±0.21 | 0.787* |
| CMT (μm) | 535.67±116.94 | 501.33±149.39 | 0.439* |
| Aldosterone level (ng/dL) | 226.04±147.97 | 158.50±103.44 | 0.087* |
| SRFH (μm) | 340.61±126.84 | 315.17±154.17 | 0.602* |
| SFCT (μm) | 502.50±87.38 | 480.33±102.38 | 0.602* |
| Patients with leakage point | 16/18 | 11/12 | 1.000† |
Values are mean±SD unless otherwise noted.
*Mann-Whitney U test.
†Fisher’s exact test.
BCVA, best corrected visual acuity; CMT, central macular thickness; logMAR, logarithm of the minimum angle of resolution; MRa, mineralocorticoid receptor antagonist; SFCT, subfoveal choroidal thickness; SRFH, height of subretinal fluid.